ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuroinfectious Diseases
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1604045
Efficacy of ceftazidime-avibactam for the treatment of central nervous system infection caused by Carbapenem-resistant Klebsiella pneumoniae after neurosurgery
Provisionally accepted
- Aviation General Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections of the central nervous system (CNS) are associated with high mortality rates. These infections are particularly challenging to treat due to both bacterial resistance and the protective blood-brain barrier. This study aims to evaluate treatment outcomes for CRKP-induced CNS infections and provide insights into effective therapeutic strategies for similar cases. Methods: A retrospective analysis was conducted on patients with CRKP-positive cerebrospinal fluid (CSF) samples admitted to the CSF Neurosurgery Department of the Aviation General Hospital between August 2019 and November 2021. Data collected included patient demographics, medical history, laboratory results, etiological findings, and antibiotic treatments. Nine patients with CRKP-induced CNS infections who were treated with Ceftazidime-avibactam (CAZ-AVI) were included in the analysis. The study assessed clinical features, treatment courses, and patient outcomes. Results: Of the nine patients, 88.9% (8/9) achieved both clinical and etiological cure. One patient experienced relapse 20 days after initial CSF culture negativity, with the family opting for discontinuation of further treatment. Following infection resolution, patients exhibited varying degrees of neurological improvement, including one case of complete recovery from a comatose state (GCS 6 to GCS 15). Treatment-related adverse effects included transient liver dysfunction in one patient and diarrhea in three, which resolved with symptomatic management. CSF drainage tubes were removed in three patients following treatment, while five required shunt surgery due to hydrocephalus. No relapses were reported in treated patients during a follow-up period of 3–12 months. Conclusion: Intravenous CAZ-AVI combined with intracerebroventricular or intrathecal polymyxin B or amikacin demonstrated promising efficacy as a treatment regimen for CRKP-induced CNS infections.
Keywords: Carbapenem-resistant Klebsiella pneumonia, Central nervous system infection, Ceftazidime-avibactam, polymyxin, tigecycline
Received: 25 Jul 2025; Accepted: 30 Sep 2025.
Copyright: © 2025 Cong, Qi, Wang, Bai, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hongwei Chen, chenhongwei173@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.